Fred Hutchinson

Participation in therapeutic drug trials appeared associated with longer OS among patients with non-small cell lung cancer, according to results of a retrospective study scheduled for presentation at Quality Care Symposium.

Sita Kugel, PhD, a scientist at Fred Hutchinson Cancer Research Center, received an NCI award that will fund her laboratory’s research into an aggressive form of pancreatic cancer.

Click here to read the Cover Story, “BCG: a real-world example of health care rationing.”

HemOnc Today held a reception at ASCO Annual Meeting to honor its third class of Next Gen Innovators.

Several distinguished leaders in hematology will be honored with awards and special lectures at this year’s ASH Annual Meeting and Exposition, scheduled for Dec. 7-10 in Orlando, Florida.

CHICAGO — Pembrolizumab exhibited an acceptable safety profile among patients with cancer and HIV who had more than 100 CD4 cells/µL and received antiretroviral therapy, according to results of a phase 1 trial presented at ASCO Annual Meeting.

NEW YORK — Petros Grivas, MD, PhD, medical oncologist and clinical director of the genitourinary cancers program at University of Washington and Fred Hutchinson Cancer Research Center, presented two talks at HemOnc Today New York.

Click here to read the Cover Story, “Advances in chronic lymphocytic leukemia suggest progress is ‘visible on the horizon’.”

The transition from primarily chemotherapy-based approaches to targeted therapies revolutionized treatment of chronic lymphocytic leukemia, the most common adult lymphoproliferative disorder in the U.S.

NEW YORK — First-line treatment of patients with metastatic renal cell carcinoma has evolved considerably in the past 18 months with FDA approval of cabozantinib monotherapy and the combination of ipilimumab and nivolumab.